Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Sao Paulo
About this trial
This is a Phase II study to determine the efficacy of SBRT to treat liver metastases in patients with Colorectal Adenocarcinoma, Carcinoma of the Anal Canal and Gastrointestinal Neuroendocrine Tumors that are not amenable to surgery. Patients should have no evidence of extra-hepatic disease or have disease that is planned to be treated with curative intent.
Therefore, SBRT is being considered as a potentially curative procedure.
Eligibility criteria
Qualifiers
Karnofsky Performance Scale (KPS) equal or greater than 70
1 to 4 liver metastases with an individual maximum diameter of up to 5 cm
Lesions considered unresectable or patients considered unfit for surgery
Histology of the primary tumor: colorectal adenocarcinoma, carcinoma of the anal canal or gastrointestinal neuroendocrine tumors.
Disqualifiers
Concomitant chemotherapy
Prior radiotherapy to the upper abdomen
Pregnancy
Underlying Cirrhosis
Trial design
Treatments tested in this trial
- SBRT
Treatment groups
43 Participants
are divided into 1 treatment groupSponsors and collaborators
University of Sao Paulo
Lead sponsor
Instituto do Cancer do Estado de São Paulo
Collaborator
Source ClinicalTrials.gov